Third Rock Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)
BoardBarbara Weber(Executive Officer, Director)in
Board seatAlexis BorisyReid Huber· per SEC Form D
Co-investorsForesite CapitalNextech InvestNSG Ventures
Septerna develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform.
BiotechDeep TechSouth San Francisco, US
Board seatJeffrey Tong· per SEC Form D · $150M raise · filed Jul 2023
Co-investorsCatalio Capital Management, LPRA CapitalSamsara BioCapitalVertex Ventures HC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.